Latest Ratios: P/E Ratio -0.2x · EV/EBITDA N/A · ROE N/A. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $17M | $28M | $46M | $44M | $193M | $652M | $203M | $238M | — |
| Enterprise Value | $52M | $63M | $114M | $109M | $245M | $645M | $179M | $237M | — |
| P/E Ratio → | -0.20 | — | — | — | 13.62 | — | — | — | — |
| P/S Ratio | 0.66 | 1.07 | 0.84 | 1.93 | 10.75 | 30.54 | 14.19 | 11.23 | — |
| P/B Ratio | — | — | 5.15 | 1.07 | 0.97 | 6.55 | 10.83 | 1.72 | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.38 | 2.10 | 4.80 | 13.62 | 30.25 | 12.53 | 11.23 | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 76.0% | 76.0% | 72.4% | 29.7% | -9.4% | 54.8% | 65.5% | 70.1% | 62.7% |
| Operating Margin | -230.9% | -230.9% | -70.7% | -844.4% | -142.4% | -511.2% | -1064.0% | -1249.0% | -0.0% |
| Net Profit Margin | -345.8% | -345.8% | -106.8% | -862.0% | 79.0% | -469.3% | -1458.4% | -1001.9% | -0.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -232.5% | -163.7% | 9.5% | -169.5% | -266.0% | -307.7% | — |
| ROA | -76.5% | -76.5% | -41.9% | -72.0% | 3.5% | -23.7% | -43.7% | -81.3% | -4.4% |
| ROIC | -125.0% | -125.0% | -31.4% | -80.9% | -11.2% | -185.1% | -171.6% | -287.5% | — |
| ROCE | -116.1% | -116.1% | -49.3% | -92.5% | -7.0% | -27.5% | -33.6% | -105.5% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 7.79 | 1.60 | 0.33 | 0.31 | 1.64 | 0.20 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | 0.03 |
| Net Debt / Equity | — | — | 7.71 | 1.59 | 0.26 | -0.06 | -1.26 | -0.00 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | 0.03 |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -12.58 | -12.58 | -8.24 | -64.10 | — | -30.57 | -89.46 | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.15 | 0.15 | 0.38 | 0.29 | 0.54 | 2.25 | 2.70 | 1.78 | 0.16 |
| Quick Ratio | 0.15 | 0.15 | 0.28 | 0.21 | 0.45 | 1.89 | 2.56 | 1.63 | -23.32 |
| Cash Ratio | 0.08 | 0.08 | 0.01 | 0.00 | 0.22 | 1.42 | 2.04 | 1.36 | 0.16 |
| Asset Turnover | — | 0.25 | 0.41 | 0.16 | 0.04 | 0.05 | 0.03 | 0.04 | 710.49 |
| Inventory Turnover | 11.14 | 11.14 | 2.77 | 2.78 | 3.70 | 1.01 | 1.28 | 1.96 | 1.85 |
| Days Sales Outstanding | — | 63.97 | 91.26 | 194.24 | 141.45 | 89.53 | 167.44 | 53.13 | 81.49 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 31.7% | 20.8% | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 7.3% | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | — |
| Total Shareholder Yield | 31.7% | 20.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | — |
| Shares Outstanding | — | $26M | $22M | $18M | $15M | $13M | $2M | $2M | $4M |
Imminent liquidity and insolvency
According to current market data, Celularity trades at a price-to-sales multiple of 0.56, which, based on reported figures, suggests the market is pricing the firm for liquidation or extreme dilution rather than the long-term potential of its placental-derived cell therapy pipeline.
The lack of meaningful P/E or EV/EBITDA multiples underscores the company's inability to generate positive earnings or operational cash flow. Investors should monitor whether this low valuation represents a deep-value opportunity or a rational reflection of the company's inability to scale its commercial operations against a massive R&D burn.
As reported in financial statements, the company's ROIC has deteriorated to -76.6% in 2025Q4, indicating that every dollar of capital invested is currently destroying shareholder value at an accelerating rate compared to historical performance.
This persistent negative return on capital suggests that the firm's specialized manufacturing infrastructure is not yet yielding the economies of scale necessary to justify its high fixed-cost base. The trend appears to indicate that the company is struggling to convert its proprietary placental processing technology into a commercially viable, return-generating asset.
Based on the provided data, the cash conversion cycle reached 622 days in 2025Q4, which, according to recent filings, highlights severe inefficiencies in managing inventory and collecting receivables relative to the company's ability to pay its own suppliers.
The extreme volatility in the CCC, swinging from negative to triple-digit positive figures, suggests that the company's operational processes are highly erratic. This lack of predictability in working capital management warrants further investigation into the underlying stability of the firm's supply chain and customer payment terms.
As reported in recent financial filings, the current ratio has plummeted to 0.15, which indicates that Celularity's liquid assets are insufficient to cover its short-term obligations, leaving the company in a highly vulnerable position under any stress scenario.
The quick ratio, mirroring the current ratio at 0.15, confirms that the firm is almost entirely dependent on its ability to raise external capital to meet immediate liabilities. This liquidity profile suggests that the company may face significant operational disruptions if it cannot secure additional funding in the immediate term.
Investors frequently misapply the price-to-sales ratio to Celularity, which, based on reported figures, obscures the fact that the company's revenue is currently insufficient to cover even a fraction of its operating expenses, rendering traditional revenue-based valuation multiples largely irrelevant for this business model.
Instead of P/S, analysts should focus on the cash-to-burn ratio and the runway remaining before the next required capital infusion. Relying on revenue multiples ignores the structural reality that the company's current commercial activities are a secondary concern compared to the existential risk posed by its clinical-stage cash burn.
Includes 30+ ratios · 8 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CELU stock.
Celularity Inc.'s current P/E ratio is -0.2x. The historical average is 13.6x.
Based on historical data, Celularity Inc. is trading at a P/E of -0.2x. Compare with industry peers and growth rates for a complete picture.
Celularity Inc.'s current dividend yield is 31.72%.
Celularity Inc. has 76.0% gross margin and -230.9% operating margin.